These include the widely used carcinogens DMBA-TPA and 4-nitroquinoline-1-oxide (4NQO), which have both been reported to result in persistent mTOR activation, leading to tumour development, and regression is observed after the administration of the mTOR inhibitor rapamycin [55,56,57]. The gene discussed is MTOR; the disease is neoplasm.